2838. Safety and Immunogenicity of a gp120-CD4 Chimeric Subunit Vaccine: A Phase 1a Randomized Controlled Trial

BACKGROUND: A primary challenge for HIV vaccine development is to raise antiviral antibodies capable of recognizing highly variable viral antigens. The full-length single chain (FLSC) gp120-CD4 chimeric protein was designed to present a highly conserved CD4-induced HIV-1 envelope structure that evok...

Descripción completa

Detalles Bibliográficos
Autores principales: Chua, Joel V, Davis, Charles, Nelson, Amy, Lam, Ka Wing J, Mutumbi, Lydiah, Stafford, Kristen A, Gilliam, Bruce, DeVico, Anthony L, Lewis, George K, Sajadi, Mohammad M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809108/
http://dx.doi.org/10.1093/ofid/ofz359.143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809108/
http://dx.doi.org/10.1093/ofid/ofz359.143

Ejemplares similares